Form 4: CalciMedica Chief Business Officer Boosts Stake with Nearly $6,500 Stock Purchase

Eric W. Roberts, Chief Business Officer, Director, and 10% Owner of CalciMedica, Inc., purchased 4,500 shares of common stock for approximately $6,482.70, increasing his total beneficial ownership to 997,410 shares.

Summary

• Eric W. Roberts, CalciMedica's Chief Business Officer, Director, and 10% Owner, acquired 4,500 shares of common stock.
• The transaction occurred on June 26, 2025, at a weighted average price of $1.4406 per share, with prices ranging from $1.43 to $1.4499.
• The total value of the purchase was approximately $6,482.70.
• Following this transaction, Mr. Roberts' total beneficial ownership in CalciMedica, Inc. stands at 997,410 shares.
• The shares were acquired indirectly through an FMTC Custodian Roth IRA, increasing that specific holding to 32,823 shares.

Sentiment

Score: 7

Explanation: The sentiment is positive due to insider buying, which typically signals confidence. However, the relatively small size of the purchase compared to total holdings prevents a higher score.

Positives

• Insider buying by a key executive (Chief Business Officer) and significant shareholder (10% Owner, Director) signals confidence in the company's future prospects.
• The purchase increases the executive's alignment with shareholder interests.

Negatives

• The transaction size of 4,500 shares is relatively small compared to Mr. Roberts' total beneficial ownership of 997,410 shares, which might suggest a limited conviction despite the purchase.

Future Outlook

The Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider purchase by a key executive in CalciMedica, a biotechnology company, is a common type of transaction in the industry. While not indicative of broader industry trends, insider buying can sometimes signal internal confidence, especially in a sector where R&D milestones and clinical trial results heavily influence stock performance.

Comparison to Industry Standards

• Insider buying is a common occurrence across all industries and is generally viewed as a positive signal.
• Without specific comparable insider transaction sizes or contexts from other biotechnology companies or executives, a detailed comparison to industry standards is not feasible based solely on this Form 4.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, potentially increasing confidence in the company's stock.
• The transaction directly impacts the beneficial ownership structure for Eric W. Roberts, aligning his interests further with other shareholders.

Key Dates

Recommendation

Keywords

CalciMedica, CALC, Eric W. Roberts, Insider Trading, Stock Purchase, Form 4, SEC Filing, Biotechnology, Pharmaceuticals, Executive Stock Ownership